Ketamin Abcur (Ketamine Hydrochloride)

Ketamine blocks the NMDA receptor by binding to its phencyclidine site, preventing calcium influx and reducing excitatory neurotransmission. This disruption of synaptic activity leads to dissociative anesthesia. Additional interactions with opioid receptors and monoaminergic pathways enhance its analgesic and, in some cases, antidepressant effects.

The dose of Ketamin Abcur is individualized by the prescribing clinician based on factors such as the patient’s age, weight, medical condition, intended use (e.g., anesthesia versus sedation), and concurrent medications. No fixed regimen is provided here; the prescriber sets the appropriate dosage and administration schedule.

Safety data for ketamine in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or used only when the potential benefit justifies the potential risk. Clinicians should evaluate the risk‑benefit ratio carefully and consider alternative therapies when possible.

To request Ketamin Abcur, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Ketamine provides dissociative anesthesia and maintains airway reflexes, whereas propofol induces a deeper hypnotic state with more pronounced respiratory depression. Ketamine also offers analgesic and sympathomimetic effects, which can be advantageous in trauma or hemodynamically unstable patients. However, ketamine may cause psychotomimetic emergence phenomena, while propofol is associated with hypotension and loss of protective reflexes.

Ketamin Abcur should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from direct sunlight, moisture, and extreme temperature fluctuations to preserve product stability.

Ketamin Abcur is supplied as a sterile injectable solution and can be administered either intramuscularly or intravenously. The route, rate of injection, and total dose are determined by the treating clinician based on the clinical indication and patient response.

The most critical risks include respiratory depression, which may require airway support; laryngospasm leading to airway obstruction; and cardiac arrhythmias that can be life‑threatening. Continuous monitoring of respiratory function, oxygen saturation, blood pressure, and heart rhythm is essential during and after administration.

Ketamin Abcur should be avoided in patients with known hypersensitivity to ketamine or its excipients, those with uncontrolled severe hypertension, individuals with a history of psychotic disorders where psychotomimetic effects could be detrimental, and patients with conditions that predispose them to increased intracranial pressure unless benefits clearly outweigh risks.